[Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer]

Hanna Besnainou; Luc Cabel

doi:10.1016/j.bulcan.2023.12.011

[Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer]

Bull Cancer. 2024 Apr;111(4):333-334. doi: 10.1016/j.bulcan.2023.12.011. Epub 2024 Mar 7.

[Article in French]

Authors

Hanna Besnainou¹, Luc Cabel²

Affiliations

¹ Département d'oncologie médicale, institut Curie, université Paris Cité, 35, rue Daily, 92210 Saint-Cloud, France. Electronic address: hannabes15@hotmail.fr.
² Département d'oncologie médicale, institut Curie, 26, rue d'Ulm, 75005 Paris, France.

PMID: 38458926
DOI: 10.1016/j.bulcan.2023.12.011

No abstract available

Keywords: Antibody-drug conjugate (ADC); Anticorps drogue-conjugués (ADC); Breast cancer; Cancer du sein; Hormone receptor positive; Récepteur hormonal positif (RH+); Sacituzumab-govitecan; Targeted therapies; Thérapies ciblées.

Publication types

Letter

MeSH terms

Breast Neoplasms* / drug therapy
Camptothecin / therapeutic use
Female
Hormones
Humans
Immunoconjugates*
Triple Negative Breast Neoplasms*

Substances

Camptothecin
Immunoconjugates
Hormones